Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $32.00 by Analysts at Piper Sandler

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) had its price objective decreased by equities researchers at Piper Sandler from $36.00 to $32.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "neutral" rating on the stock. Piper Sandler's price objective suggests a potential upside of 12.70% from the stock's previous close.

Separately, Wells Fargo & Company initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 target price on the stock.

Amphastar Pharmaceuticals Trading Up 0.4 %

Amphastar Pharmaceuticals stock traded up $0.11 during mid-day trading on Friday, hitting $28.40. The company's stock had a trading volume of 225,696 shares, compared to its average volume of 425,961. Amphastar Pharmaceuticals has a 1 year low of $25.89 and a 1 year high of $53.96. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm has a market capitalization of $1.35 billion, a PE ratio of 9.46, a price-to-earnings-growth ratio of 2.19 and a beta of 0.77. The stock's fifty day moving average is $31.91 and its two-hundred day moving average is $40.48.

Insider Activity

In related news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total transaction of $116,521.74. Following the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.10% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Amphastar Pharmaceuticals

A number of large investors have recently modified their holdings of AMPH. Tower Research Capital LLC TRC grew its stake in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after purchasing an additional 348 shares in the last quarter. Huntington National Bank boosted its position in shares of Amphastar Pharmaceuticals by 36.9% during the 4th quarter. Huntington National Bank now owns 1,340 shares of the company's stock worth $50,000 after acquiring an additional 361 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Amphastar Pharmaceuticals by 4.6% in the 4th quarter. Bank of Montreal Can now owns 8,215 shares of the company's stock valued at $305,000 after acquiring an additional 361 shares during the last quarter. TD Private Client Wealth LLC raised its position in shares of Amphastar Pharmaceuticals by 22.7% during the 4th quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company's stock worth $78,000 after acquiring an additional 388 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. lifted its stake in Amphastar Pharmaceuticals by 53.4% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company's stock worth $56,000 after purchasing an additional 398 shares during the last quarter. 65.09% of the stock is owned by hedge funds and other institutional investors.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.